hydroxychloroquine inhalation (HCQ01) / Sana Pharma - LARVOL DELTA

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: King Hussein Cancer Center | N=28 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Oncology • Solid Tumor

Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers. (PubMed, J Aerosol Med Pulm Drug Deliv) - "The reported systemic exposure was very low with a mean value of 5.28 (0.6-15.6) ng·h/mL. The low systemic concentrations of HCQ01 of 9.66 ng/mL reported by our study compared with 1 μg/mL previously predicted after 200 mg BID oral administration, and the safety and tolerability of HCQ01 administered as a single dose through nebulization, support the assessment of its efficacy, safety, and tolerability in further studies for the treatment of COVID-19."

Journal • PK/PD data • Hematological Disorders • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - P1/2 | N=28 | Not yet recruiting | Sponsor: King Hussein Cancer Center | Trial completion date: Jan 2022 ➔ Dec 2022 | Trial primary completion date: Jan 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Oncology • Solid Tumor

The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19 (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: Ministry of Health Jordan | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2021 ➔ Mar 2022

Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease

The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19 (clinicaltrials.gov) - P2; N=110; Not yet recruiting; Sponsor: Ministry of Health Jordan

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - P1/2; N=28; Not yet recruiting; Sponsor: King Hussein Cancer Center; Trial completion date: Sep 2021 ➔ Jan 2022; Initiation date: Mar 2021 ➔ Jul 2021; Trial primary completion date: Sep 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Oncology • Solid Tumor • PCR

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov) - P1/2; N=28; Not yet recruiting; Sponsor: King Hussein Cancer Center

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Oncology • Solid Tumor • PCR